Skip to main content

Advertisement

SpringerLink
Log in

Fatal exacerbation of paraneoplastic systemic sclerosis after neoadjuvant chemotherapy in a breast cancer patient

  • Case Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Paraneoplastic systemic sclerosis (SSc) occurs in about 3%–7% of individuals with SSc. There are reports of accelerated SSc syndromes associated in particular with breast cancer. Further exacerbations of the rheumatic condition may be induced by treatment of the cancer. We report a 30-year-old African-American woman with a contiguous diagnosis of breast cancer and paraneoplastic SSc. She was treated with neoadjuvant chemotherapy and developed an accelerated SSc syndrome with pericarditis and cardiac tamponade, with lethal results. This case report stresses the need for control of the rheumatic condition prior to the initiation of antineoplastic therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

CTGF:

Connective tissue growth factor

EC:

Endothelial cells

SSc:

Systemic sclerosis

TGF:

Transforming growth factor

TNF:

Tumor necrosis factor

References

  1. Postlethwaite AE (1990) Early immune events in scleroderma. Rheum Dis Clin North Am16:125–139

    Google Scholar 

  2. White B (1995) Immunologic aspects of scleroderma. Curr Opin Rheumatol 7:541–545

    CAS  PubMed  Google Scholar 

  3. Whiteside TL, Kumagai Y, Roumm AD, Almendinger R, Rodnan GP (1983) Suppressor cell function and T lymphocyte subpopulations in peripheral blood of patients with progressive systemic sclerosis. Arthritis Rheum 26:841–847

    CAS  PubMed  Google Scholar 

  4. Gustafsson R, Totterman TH, Klareskog L, Hallgren R (1990) Increase in activated T cells and reduction in suppressor inducer T cells in systemic sclerosis. Ann Rheum Dis49:40–45

    Google Scholar 

  5. Kahaleh MB (1991) Soluble immunologic products in scleroderma sera. Clin Immunol Immunopathol 58:139–144

    CAS  PubMed  Google Scholar 

  6. Duncan SC, Winkelmann RK (1979) Cancer and Scleroderma. Arch Dermatol 115:950–955

    CAS  PubMed  Google Scholar 

  7. Thomas E, Brewster DH, Black RJ, MacFarlane GJ (2000) Risk of malignancy among patients with rhematic conditions. Int J Cancer 88:497–502

    Article  CAS  PubMed  Google Scholar 

  8. Lee P, Alderdice C, Wilkinson S, Keystone EC, Urowitz MB, Gladman DD (1985) Malignancy in systemic sclerosis. J Rheumatol 12:1136–1138

    CAS  PubMed  Google Scholar 

  9. Hill CL, Nguyen AM, Roder D, Roberts-Thomson (2003) Risk of cancer in patients with scleroderm: a population based cohort study. Ann Rheum Dis 62:728–731

    Article  CAS  PubMed  Google Scholar 

  10. Pearson JE, Silman AJ (2003) Risk of cancer in patients with scleroderma. Ann Rheum Dis 62:697–699

    Article  CAS  PubMed  Google Scholar 

  11. Querfeld C, Collbeg S, Huerkamp C, Eckes B, Krieg T (2000) Pseudoscleroderma associated with lung cancer: correlation of collagen type I and connective tissue growth factor gene expression. Br J Dermatol 142:1228–1233

    Article  CAS  PubMed  Google Scholar 

  12. Bielefeld P (1991) Systemic scleroderma and malignant disease. A review of the literature. Rev Med Interne 12:350-354

    CAS  PubMed  Google Scholar 

  13. Berd D, Mastrangelo MJ (1987) Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subset. Cancer Res 47:3317–3321

    CAS  PubMed  Google Scholar 

  14. Bast RC Jr, Reinherz EL, Maver C, Lavin P, Schlossman SF (1983) Contrasting effects of cyclophosphamide and prednisolone on the phenotype of human peripheral blood leukocytes. Clin Immunol Immunopathol 28:101–114

    PubMed  Google Scholar 

  15. Booton R, Jeffery R, Prabhu PN (1999) Systemic sclerosis and scleroderma renal crisis in association with carcinoma of the breast. Am J Kidney Dis 34:937–941

    CAS  PubMed  Google Scholar 

  16. Dewani MS, Qadri SR, Lone MA, Qureshi KA (2000) Progressive systemic sclerosis (scleroderma), carcinoma breast and valvular heart disease: an unusual combination. J Postgrad Med 46:181–183

    CAS  PubMed  Google Scholar 

  17. Puett DW, Fuchs HA (1994) Rapid exacerbation of scleroderma in a patient treated with interleukin-2 and lymphokine-activated killer cells for renal cell carcinoma. J Rheumatol 21:752

    CAS  PubMed  Google Scholar 

  18. Abdul Hamied TA, Parker D, Turk JL (1987) Effects of adriamycin, 4-hydroperoxycyclophosphamide and ASTA Z 7557 (INN mafosfamide) on the release of IL-2 and IL-1 in vitro. Int JImmunopharmacol 9:355–361

    Article  Google Scholar 

  19. Goronzy JJ, Weyand CM (1990) Long-term immunomodulatory effects of T lymphocyte depletion in patients with systemic sclerosis. Arthritis Rheum 33:511–519

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Winship Cancer Institute, Emory University School of Medicine, PO Box 55440, Atlanta, GA 30308, USA

    Ruby Kochhar & Jay N. Umbreit

Authors
  1. Ruby Kochhar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jay N. Umbreit
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ruby Kochhar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kochhar, R., Umbreit, J.N. Fatal exacerbation of paraneoplastic systemic sclerosis after neoadjuvant chemotherapy in a breast cancer patient. Clin Rheumatol 23, 269–271 (2004). https://doi.org/10.1007/s10067-004-0875-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-004-0875-x

Keywords

Search

Navigation